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Abstract  
 
Theranostics involves finding the biomarkers of a disease, fighting them through site specific 
drug delivery and following them for prognosis of the disease. Microneedle array technology 
has been used for drug delivery and extended for continuous monitoring of analytes present in 
the skin compartment. We envisage the use of microneedle arrays for future theranostic 
applications. The potential of using combined microneedle array-based drug delivery and 
diagnostics as part of closed-loop control system for the management of diseases and delivery 
of precision drugs in individual patients, is reported in this paper. 
 
Abbreviations: 
 
MNA: Microneedle arrays; ISF: Interstitial fluid; CGM: continuous glucose monitoring; TDM: 
Therapeutic drug monitoring; PK: pharmacokinetics; PD: pharmacodynamics;  
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1.0 Introduction: 
The concept of “theranostics” refers to the find, fight and follow strategy, which is used for 
personalised patient treatment involving diagnosis and therapy (Figure 1). (Riehemann, 2009) 
Although the term “theranostics” was coined by Funkhouser (Funkhouser, 2002) to indicate 
the amalgamation of diagnostics and therapeutic potential into a single agent, this concept dates 
back to more than 70 years with nuclear medicine practices employing radionuclides for 
management of cancer. (Levine, 2017) Seidlin et al published the first study on radioiodine 
therapy for diagnostic imaging and target-expression confirmation in metastatic thyroid cancer. 
(Seidlin,1946)  Peptide receptor scintigraphy (PRS) for imaging cancer and 90Y and 177Lu 
radionuclides for peptide receptor radionuclide therapy (PRRT) for treatment of 
neuroendocrine tumours is one of the most successful examples of the theranostic concept. 
(Krenning, 1989)  
Insert Figure 1 here 
Current theranostic approaches combining imaging and therapy are based on the developments 
in the area of nanomedicine. (Kelkar, 2011) Appropriate probes such as contrast agents, 
fluorescent markers and nuclear image agents are used to find the heterogeneity of the tumour 
using Magnetic resonance imaging (MRI), Near Infra-Red (NIR) fluorescence and Positron 
Emission Tomography/ Single Photon Emission Computed Tomography (PET/SPECT/CT) 
techniques, respectively. The delivery of therapeutic drugs to fight the tumour includes 
strategies such as nucleic acid delivery, chemotherapy, hyperthermia in photothermal ablation, 
photodynamic and radiation therapy. (Ho, 2010) & (Riehemann, 2009) The effects of the 
therapy can then be followed by imaging the probes. 
The nanoparticles and nanomaterials used as carriers include various inorganic nanoparticles 
(noble metal, metal oxide, and mesoporous silica nanoparticles, semiconductor quantum dots, 
and magnetic nanoparticles), organic systems (such as liposomes, peptide assemblies and 
exosomes) and synthetic polymer systems (such as vesicles and micelles). These inorganic 
nanoparticles often have unique physicochemical properties that allow applications in imaging 
and even therapy for example, photothermal ablation and magnetic fluid hyperthermia.  
Liposomes, peptides and polymer nanoparticles have the capacity to carry various molecules, 
such as DNA, RNA, proteins, enzymes, and lipophilic organic drugs. They can also be further 
tagged with imaging labels. Oncologists rely on integration of information derived from a 
diagnostic test for drug selection which allows patient stratification ultimately leading to 
personalised medicine.  
The global theranostic market size was estimated at USD 5.62 billion in 2016 and is expected 
to reach USD 18.3 billion by 2025, according to a new report by Grand View Research, Inc. 
(web reference1) Diagnostics is coming to grips with the wave of pharmacogenomic tests that 
are followed by new biological therapy introductions. These tests enable cost-effective 
treatment that add value to the process of patient-stratification. Advantages associated with the 
usage of these tests such as; disease risk prediction, patient stratification, and therapeutic 
response monitoring over the traditional methods is anticipated to be a significant source of 
progress in this market. (web reference2)   
In an ideal scenario, effective drugs would allow selective and rapid accumulation in diseased 
tissue, report on biochemical and morphological characteristics of the tissue of interest, deliver 
effective therapy, be safe and biodegradable with non-toxic by products, and lack 
immunogenicity. However, due to the complexity of nanoparticles in terms of toxicity and non-
biodegradability, the clinical translation is not simple and straightforward. In addition, there 
are a number of biological barriers in the living subject that challenge the efficacy of 
nanoparticle delivery. These include walls of blood vessels, physical entrapment of particles in 
tissue and capillaries, opsonisation and removal of particles by phagocytic cells.  
Robust processes that facilitate scale-up and manufacturing are a pre-requisite. Studies of 
biological responses to nanoparticles need to consider many factors, including exposure levels, 
systemic accumulation, excretion profiles, tissue and organ distributions, and the 
characteristics (age, gender, etc.) of test subjects. It is essential to investigate and understand 
potential toxic responses, particularly long-term toxic effects, before they may be tested in 
humans to image and treat diseases. 
Validation of novel methods for theranostic applications is required. This will include looking 
at alternate means of drug delivery and monitoring therapeutic benefits over disease 
progression. One potential approach for future theranostic applications is the development of 
closed-loop systems based on Microneedle Array (MNA) devices accessing the skin 
compartment matrix. Typically ranging from 400 – 1000 µM in height, MNAs can penetrate 
the stratum corneum and sit in the dermal interstitial fluid (ISF). This offers a minimally 
invasive means for real time monitoring of analytes present in the ISF. Similarly, MNAs can 
be used for precision drug delivery and the transdermal route is known to increase the 
“bioavailability” of the drug. We report the current state of the art within the field of 
Microneedle arrays that offers a novel approach for the development of MNA based closed 
loop systems. 
2.0 Concept of microneedle arrays platform for future theranostic applications 
The key concepts of a MNA based theranostic system for personalised medicine have been 
outlined in Figure 2. Ideally, monitoring of the therapeutics should be done continuously or 
frequently in a minimally invasive format. MNAs as electrochemical biosensors for continuous 
glucose monitoring has already been tested in Type 1 diabetics, demonstrating their safety, 
tolerability and performance. (Sharma, 2018) 
Insert Figure 2 here 
Given that the concentration of several analytes of clinical significance (Tran, 2018), (Paliwal, 
2013) in the ISF are generally in equilibrium with the blood concentration, MNAs can be used 
to monitor ISF concentrations and estimate blood concentration of the analytes in near real-
time without requiring blood sampling. However, it may also offer a novel option for chronic 
skin diseases where the relevant analyte concentrations would be higher than that in blood. For 
diseases, where the biomarker concentration is very low or does not correlate with the blood 
concentration, MNA arrays can be used for diagnostic purposes and therapeutic drug 
monitoring (TDM) in the ISF. TDM linked with Bayesian forecasting provides a powerful 
opportunity for delivering individualised care for patients. (Roberts, 2014), (Felton, 2014)  
Data generated by the MNA sensors can then be linked with machine-driven, closed loop 
control algorithms such as Proportional- Integral-Derivative (PID) and Iterative learning 
controllers (ILC) to allow for the optimization of therapeutic agent delivered by the MNAs. 
The drug delivery MNAs comprise of either solid microneedles coated with responsive 
hydrogels or hollow microneedles through which the drugs can be delivered using an infusion 
pump.  
Although theranostic approaches have been primarily used for cancer, the MNAs reported here 
are anticipated to address other clinical challenges such as skin, metabolic and infectious 
diseases. The current state of art of each of the component of the closed-loop theranostic MNA 
are further described in the next sections. 
3.0 Microneedle arrays for monitoring in dermal ISF  
Microneedle arrays (MNAs) were introduced mainly for transdermal delivery of drugs and 
vaccines. (Henry, 1998)  Their diagnostic prowess has been exploited in the last decade to 
monitor metabolites such as glucose and lactate in the skin compartment. (Trzebinski, 2012) 
They offer a minimally invasive route for monitoring of metabolites and drugs. The 
commercially available continuous glucose monitoring sensors are expensive to fabricate and 
thus usually implanted into the subcutaneous tissue for a duration of 10-14 days, leading to 
biofouling of the sensor surface and thus explains the false alarms and poor acceptability 
(<10%). To address these issues associated with costs and biofouling, minimally invasive 
polycarbonate MNAs have been fabricated using high throughput technologies at very low 
costs. (Sharma, 2017) Microneedle arrays for continuous glucose monitoring applications have 
been extensively reviewed elsewhere. (El-Laboudi, 2013) 
Insert Figure 3 here 
Using injection moulding, more than 1000 polycarbonate MNAs can be produced in a day with 
the cost of polycarbonate being a few pence. These MNAs also were tested on force stations 
and shown to withstand axial forces of up to 400 N. Optical coherence tomography of the 
MNAs indicate that these can penetrate human skin under moderate thumb pressure (<10N). 
(Sharma, 2017) In a human pilot study conducted in healthy volunteers and participants with 
Type 1 diabetes, it has been established that the occurrence of infection, bleeding and pain have 
not been reported, and these MNA have been reportedly tolerated very well in both healthy 
volunteers and participants with Type 1 diabetes studies. (Sharma, 2018) 
So far, MNAs have been modified to fabricate electrochemical sensors and used for monitoring 
metabolites (glucose and lactate), drugs such as theophylline (Sharma, 2017) and penicillin 
(Rawson 2017). This is done either entrapping the molecular recognition element (in the case 
of glucose sensors it is the enzyme glucose oxidase) either in a polymer such as 
electropolymerised polyphenol (Sharma, 2016) or in hydrogels on platinum or graphene (Lee, 
2016) coated MNAs. 
Eltayib et al have reported minimally invasive monitoring MNAs for monitoring lithium. 
(Eltayib, 2016) Similar experiment in Morris’s lab, show the potential of MNAs to access 
intracellular CDK4 thanks to specific peptide substrates (Prével, 2016), in both cultured cells 
and frozen skin samples onto which they were applied.  Western blot analyses reveal that CDK4 
can be found on the microneedle arrays following insertion into A375 melanoma cells grown 
on plastic dishes.   
4.0 Microneedle arrays for transdermal drug delivery:  
Limitations of oral (Sastry, 2000) and parenteral (Simoneson, 1999) drug delivery have led to 
alternate approaches such as transdermal drug delivery. Transdermal drug delivery offers many 
benefits such as; avoidance of first-pass metabolism, prevention of gastrointestinal 
degradation, ability to maintain relatively constant plasma concentrations and increased patient 
compliance. (Molinuevo, 2012) However, the stratum corneum layer acts as an excellent 
barrier, consequently, transdermal delivery has been limited by the lack of molecules 
possessing the required physicochemical properties to passively cross it. Various chemical and 
physical methods have been investigated to reduce the barrier effects of the stratum corneum 
and reap the benefits of transdermal delivery. Microneedle array (MNA) technology for 
enhanced transdermal drug delivery has received particular attention and is rapidly progressing 
towards commercialisation.  
MNAs for drug delivery were introduced in the 1970s and since then, they have been fabricated 
by a variety of methods, from a range of materials, in varying geometries. These minimally 
invasive devices, puncture the stratum corneum, forming aqueous conduits through which 
drugs diffuse to dermal microcirculation. This technology marries the patient-friendly benefits 
of a transdermal patch with the advantage of delivering drugs through the stratum corneum. 
The MNAs penetrate the stratum corneum and sit sufficiently in the dermal space to enable 
access to the skin’s rich microcirculation, yet with a length varying from 50 - 900 µm, they are 
short enough to avoid stimulation of dermal nerves. (Donnelly, 2011) 
MNs have been employed in five different formats for drug delivery. These include, solid 
(Ling-Teo, 2005; Douroumis , 2018), coated (Zhu, 2012), dissolving (Migalska, 2011), hollow 
(Gardeniers, 2003) and swelling (Donnelly, 2014). They can be developed using different 
materials such as metal (Martanto, 2006), glass (Martanto, 2004), silicon (Ji, 2006), 
carbohydrates (Martin, 2012) and polymers (both solid and dissolving) (Donnelly, 2013). 
These MNAs increase the number of compounds amenable to transdermal delivery by 
penetrating the stratum corneum and creating a pathway for drug permeation to the dermal 
tissue below. MNAs for drug delivery applications have reviewed elsewhere. (Larrañeta, 2016) 
Regulatory guidance is needed alongside scale-up of the technology to progress towards a 
commercially available MNA product. There are a number of patient factors relating to safety, 
usability and long-term use of MNAs which will need to be addressed moving forward.  
5.0 Closed-loop control for drug delivery 
Closed-loop controllers (CLCs) have a been employed particularly in the field of diabetes and 
have been instrumental in the developments of the artificial pancreas system. (Absalom, 2002), 
(Madhavan, 2011) Furthermore, they have been demonstrated as effective during surgical 
procedures, in controlling delivery of both intravenous and inhaled anaesthetic agents during 
surgery. (Madhavan, 2011) CLCs have also been demonstrated in pre-clinical and in silico 
studies for the optimisation of antimicrobial dosing. (Gorchkov , 1996), (Ulldemolins, 2014) 
Two of the most widely used controllers for continuous and intermittent bolus infusions are the 
PID and ILC controllers, respectively. (Frimodt-Møller , 2002) These controllers are 
algorithms that optimize the delivery of an agent against a pre-determined set point.  
5.1 Proportional-Integral-Derivative (PID) control 
PID controllers depend on frequent or constant monitoring and can be used to control 
continuous infusions maintaining drug concentrations at a set target (for example either target 
concentration or pharmacokinetic-pharmacodynamics (PK-PD) index). PID has three 
coefficients; the proportional, integral, and derivative. It alters these three coefficients to 
optimize the response against its target for therapy. The simplicity and robustness of PID 
algorithms make them extremely suitable for a plethora of healthcare applications. One such 
example is acute treatment or critical care units for continuous infusions of beta-lactam 
antimicrobials and vancomycin, which are nephrotoxic, to optimize the PK exposure and PD 
properties. (Johnson, 2005), (Cataldo, 2012) Moreover, it enables a real time response in 
accordance to individual patient PK especially when there are differences in the patient PK 
from that measured through therapeutic drug monitoring in blood samples. (Chagnac, 2000)  
5.2 Iterative Learning Control in closed-loop control 
Iterative Learning Control (ILC) relies on information obtained from continuous or real time 
monitoring of a biomarker and thus facilitates optimization of bolus or drug therapy. (Madady, 
2008) The information from continuous monitoring is used to optimize the amount, timing, and 
rate at which a drug is delivered. Similar to PID, ILC algorithms have wide applications but 
work on the assumption that during repetitive tasks there will be some level of error in target 
attainment (for example an overshoot or an undershoot). Therefore, the input, such as the bolus 
dose, is adjusted to reduce the transient error encountered during routine drug delivery, in order 
to optimize the accuracy in closed loop systems. This will be more applicable to theranostic 
applications of microneedle arrays especially in a simpler setting, for example using theranostic 
MNA patches for drug dosing. It can also be extended to specialist populations, such as 
pediatrics and pregnancy, where rich data collection will allow for tailored therapy to be 
determined and adjusted, based on real time data and potentially utilizing previous experience 
housed within machine learning algorithms. A classic example of this is the Case-Based-
Reasoning in diabetes management. (Herrero, 2015) Both PID and ILC systems can 
automatically control the delivery of an agent in optimised precision drug delivery.  
6.0 Discussion and Conclusions 
The biggest challenge in translating microneedle array based electrochemical sensors and 
microneedle arrays drug delivery into a closed-loop control system is the accuracy of the MNA 
sensors especially during the initial phase of monitoring, when the sensors baseline has not 
reached a steady state. Sensor warm up time for electrochemical sensors has been reported in 
the literature (Sharma 2018). Addressing this issue will impact the further development of 
MNA theranostic closed loop systems. 
 
As demonstrated in this paper, MNA technology has been successfully implemented for 
discrete diagnostic and drug delivery applications. Interfacing the two theranostic components 
using closed loop systems will offer MNAs based devices for future theranostic applications. 
Future MNA based theranostic devices will either measure analytes of clinical significance in 
the skin compartment or measure the drug/ metabolite concentrations in response to a drug 
therapy. Both these approaches will allow personalization of the drug therapy through precision 
delivery of drugs. 
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Captions: 
 
Figure 1: Showing concept of theranostics.  
Figure 2: Showing the schematic for a closed-loop control microneedle arrays theranostic 
device. Left (top): MNA sensors (bottom): SEM of Hollow drug delivery MNAs. Right: The 
red dotted circle showing the microneedle arrays patches stuck on the forearm of a healthy 
volunteer; the white dotted circle showing a PCB based device with a controller for the 
potentiostat and the infusion pump. 
Figure 3: Showing SEM images of MNAs made in different ways using different materials. 
(a) MNAs fabricated by photolithography of SU8 100; (b)MNAs made by casting PDMS 
moulds with SU8 50 followed by UV cross linking and (c)MNAs fabricated using injection 
moulding of polycarbonate. 
Figure 4: Western blot showing amount of CDK4 proteins extracted by insertion of 
microneedle arrays array structures. Here C1 and C2 represent conditions in which the 
microneedle arrays were gently tapped into the skin 3-4 times and then rinsed with 50ul PBS 
and microneedle arrays left in the skin sample for 5 minutes under moderate thumb pressure 
followed by rinsing with PBS, respectively. As evident from the Western blot, there is plenty 
of CDK4 in condition C2. 
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